Loading
Low-PV asked whether even low-risk patients gain from interferon: more of them stayed at the haematocrit target without progression when ropeginterferon was added to phlebotomy.
Low-PV randomised 127 patients with low-risk PV (under 60 with no prior thrombosis) to phlebotomy plus low-dose aspirin with or without ropeginterferon alfa-2b. At 12 months, 84 percent on ropeginterferon kept a haematocrit at or below 45 percent without progressive disease versus 60 percent with phlebotomy alone (Barbui and colleagues, Lancet Haematology 2021), with fewer phlebotomies and no excess serious harm; the benefit held at two years.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
127 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Response at 12 monthsprimary | Ropeginterferon + phlebotomy | 64 | 84% | - | - | - |
| Phlebotomy alone | 63 | 60% |
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV), Cytokines & engineered cytokines and the tags polycythaemia-vera, mpn.
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Hepcidin-based control as first-line treatment in low-risk polycythaemia vera, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.